Halozyme Therapeutics Inc. (HALO) announced Friday morning that it has entered into a worldwide Collaboration and License Agreement with Pfizer Inc. (PFE) to develop and commercialize products combining proprietary Pfizer biologics with Halozyme's Enhanze technology.
Halozyme Therapeutics gapped up sharply Friday and climbed throughout the first half of the morning. Shares finished up by 1.49 at $7.01, with volume at over a 4-month high. The stock broke out to a 2 1/2 month high.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org